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Fibroblast growth factor 21 (FGF21) is a hepatokine that
during fasting (in the absence of insulin and dietary nutri-
ents) plays an important role in the adaptive response to
starvation. However, in the setting of obesity and nutrient
excess, FGF21 has potent pharmacologic effects that
include weight loss and improved insulin sensitivity due in
large part to FGF21’s ability to mount a robust thermo-
genic response. FGF21 is also a target gene of PPARa and
PPARg agonists, and mediates many of the effects of these
agonists in liver and adipose tissue. Although these effects
make FGF21 an attractive therapeutic target for obesity,
FGF21 also inhibits growth, causes bone loss, and sup-
presses female reproduction. Interestingly, many of the
pharmacologic effects seen in obese mice are also part of
the adaptive physiologic response seen in starvation. To
understand the anatomical sites of FGF21 action, we have
generated whole-body and tissue-selective knockouts of
b-Klotho, the co-receptor believed to be required for
FGF21 signaling. All of the known effects of FGF21 are
lost in b-Klotho knockout mice. Selective elimination of
b-Klotho in a number of different tissues, including
adipose, liver, and particularly in the CNS has revealed the
existence of a complex peripheral and neural endocrine
circuit, which coordinates the diverse physiologic and
pharmacologic actions of FGF21.
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